Leerink upgraded Eli Lilly (LLY) to Outperform from Market Perform with a price target of $1,104, up from $886. The firm expects multiple waves of obesity treatment adoption drivers, led by significantly expanded Medicare and Medicaid access by January 2027 and Lilly’s launches of orforglipron, retatrutide, and eloralintide to strengthen the company’s leadership position, the analyst tells investors. The firm, which increased its 2026-2030E EPS by 4-9% annually, boosted its five-year revenue compound annual growth view from 12% to 15%.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- SanegeneBio announces RNAi licensing, collaboration with Lilly
- Pfizer Clinches $10 Billion Metsera Deal as Novo Nordisk Loses Weight-Loss Drug Battle
- Insider Moves: JPMorgan, Adobe, Eli Lilly, McDonald’s, Merck
- Trump Weekly: China to suspend some controls on rare earths
- Eli Lilly price target raised to $1,090 from $1,069 at Morgan Stanley